WO2005051955A1 - 新規化合物および医薬組成物 - Google Patents
新規化合物および医薬組成物 Download PDFInfo
- Publication number
- WO2005051955A1 WO2005051955A1 PCT/JP2004/017480 JP2004017480W WO2005051955A1 WO 2005051955 A1 WO2005051955 A1 WO 2005051955A1 JP 2004017480 W JP2004017480 W JP 2004017480W WO 2005051955 A1 WO2005051955 A1 WO 2005051955A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- general formula
- compound represented
- compounds
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 113
- 239000000203 mixture Substances 0.000 title claims description 105
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 17
- 241000196324 Embryophyta Species 0.000 claims abstract description 14
- 241000208838 Asteraceae Species 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 32
- 238000004587 chromatography analysis Methods 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 239000003183 carcinogenic agent Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- -1 3-hydroxy-1-butenyl group Chemical group 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000004255 ion exchange chromatography Methods 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims 9
- 239000003560 cancer drug Substances 0.000 claims 2
- 238000010898 silica gel chromatography Methods 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- NQTBGYYRPIDDKV-UHFFFAOYSA-N Tagitinin F Natural products CC(C)C(=O)OC1CC2(C)OC(O)(C=C2)C(=C3/CC1C(=C)C(=O)O3)C NQTBGYYRPIDDKV-UHFFFAOYSA-N 0.000 description 21
- VKWNXJLVNFOOOS-UHFFFAOYSA-N tirotundine Chemical compound CC1CC2OC(=O)C(=C)C2C(OC(=O)C(C)C)CC2(C)CCC1(O)O2 VKWNXJLVNFOOOS-UHFFFAOYSA-N 0.000 description 20
- 230000002441 reversible effect Effects 0.000 description 18
- 238000002955 isolation Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- SOLCYTMIFQPNDN-UHFFFAOYSA-N (3R,4S,6R,7S,8R,10S)-3-methoxy-3,10-epoxy-8-isobutyryloxygermacra-11(13)-en-6,12-olide Natural products COC12CCC(C)(CC(OC(=O)C(C)C)C3C(CC1C)OC(=O)C3=C)O2 SOLCYTMIFQPNDN-UHFFFAOYSA-N 0.000 description 10
- VFGYNAKTBUVRDH-UHFFFAOYSA-N Tagitinin C Natural products CC(C)C(=O)OC1CC(C)(O)C2=CC(=O)C(=CC23OC(=O)C(=C)C13)C VFGYNAKTBUVRDH-UHFFFAOYSA-N 0.000 description 9
- QSOMGPFBPSJEFH-UHFFFAOYSA-N desacetylviguiestenin Natural products C1C(O)C(C)=CC2OC(=O)C(=C)C2C(OC(=O)C(C)C)CC2(C)OC21 QSOMGPFBPSJEFH-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 241000220479 Acacia Species 0.000 description 5
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001513033 Tithonia Species 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 235000003325 Ilex Nutrition 0.000 description 2
- 241000209035 Ilex Species 0.000 description 2
- 240000001931 Ludwigia octovalvis Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 240000009010 Tithonia diversifolia Species 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- POSWICCRDBKBMH-UHFFFAOYSA-N dihydroisophorone Natural products CC1CC(=O)CC(C)(C)C1 POSWICCRDBKBMH-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SDILYIBSLKZODH-UHFFFAOYSA-N 3,5,6,7-tetrahydroxy-2-phenylchromen-4-one Chemical compound OC=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 SDILYIBSLKZODH-UHFFFAOYSA-N 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000567769 Isurus oxyrinchus Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100286123 Mus musculus Hoxa1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- VKWNXJLVNFOOOS-QNIDSSLUSA-N Tagitinin D Natural products CC(C)C(=O)O[C@@H]([C@H]1C(=C)C(=O)O[C@@H]1C[C@@H]1C)C[C@]2(C)CC[C@@]1(O)O2 VKWNXJLVNFOOOS-QNIDSSLUSA-N 0.000 description 1
- QSOMGPFBPSJEFH-NCOPGYRHSA-N Tagitinin E Natural products O=C(O[C@H]1[C@@H]2C(=C)C(=O)O[C@H]2/C=C(\C)/[C@@H](O)C[C@@H]2[C@@](C)(O2)C1)C(C)C QSOMGPFBPSJEFH-NCOPGYRHSA-N 0.000 description 1
- XJUPOHKZSDZNBE-QDHYIOMWSA-N Tagitinin F Chemical compound CC(C)C(=O)O[C@@H]([C@H]1C(=C)C(=O)O[C@@H]1\C=C/1C)C[C@]2(C)C=C[C@@]\1(O)O2 XJUPOHKZSDZNBE-QDHYIOMWSA-N 0.000 description 1
- 244000002460 Tithonia rotundifolia Species 0.000 description 1
- DUQSSEQKLJQACA-FESGBCJUSA-N [(3ar,4r,6r,7e,10z,11ar)-6-hydroxy-6,10-dimethyl-3-methylidene-2,9-dioxo-3a,4,5,11a-tetrahydrocyclodeca[b]furan-4-yl] 2-methylpropanoate Chemical compound CC(C)C(=O)O[C@@H]1C[C@@](C)(O)\C=C\C(=O)\C(C)=C/[C@H]2OC(=O)C(=C)[C@H]12 DUQSSEQKLJQACA-FESGBCJUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QSOMGPFBPSJEFH-UXBLZVDNSA-N tagitinins Chemical compound C1C(O)\C(C)=C\C2OC(=O)C(=C)C2C(OC(=O)C(C)C)CC2(C)OC21 QSOMGPFBPSJEFH-UXBLZVDNSA-N 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/80—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Definitions
- the present invention relates to a novel compound, in particular, a novel compound extracted and isolated from a plant of the genus Asteraceae or a plant of the genus Ilex in the family Acacia and the use thereof.
- the present invention also relates to a medicinal use of a known substance extracted and isolated from asteraceae plants or acacia genus plant power.
- Asteraceae plants or Acacia genus plants of the genus Apocynaceae, in particular,-Tobegiku are known to have pharmacological effects such as suppression of skin diseases (athlete's foot disease), hepatitis, jaundice and cystitis. You.
- a remedy for diabetes using a decoction of citrus or an extract thereof is proposed.
- R and R each represent a hydroxyl group (hereinafter referred to as “TD-7”), and R is hydrogen
- R represents a hydrogen atom
- R represents a hydrogen atom
- TD-10 A compound exhibiting an R-force methoxy group
- TD-1 A compound exhibiting an R and R force S methoxy group
- TD-8 (Hereinafter referred to as “TD-8”) has been disclosed.
- Tagitun F is TD-1 in the present invention. It is not equivalent to one ten.
- TD-11 (Hereinafter referred to as “TD-11”) has been disclosed.
- TD-12 (Hereinafter, referred to as “TD-12”) are disclosed.
- TD-13 (Hereinafter, “TD-13” t) is disclosed.
- Patent Document 1 Patent No. 2609780 (Japan)
- Patent Document 2 Japanese Patent Application No. 8-127538 (Japan)
- Technical literature ll Isao Agata, et al. Yakugaku zasshi, 101, 1067-1071 (1981)
- Technical literature 12 S. Shibata, et al. Yakugaku Zasshi, 80, 620-624 (1960)
- Technical literature 13 Christa Zdero, et al. Phytochemistry, 26, 1999-2006 (1987) Summary of the Invention
- the present inventors have now found that a novel compound having an anticancer effect and that a known compound has an anticancer effect on specific cancer cells.
- the present invention is based on powerful findings. Accordingly, the present invention provides a novel compound and a pharmaceutical use of a known compound having anticancer properties against a specific cancer.
- a novel compound can be provided, and the compound is represented by the following general formula.
- R represents an acid group
- TD-3 (Hereinafter, referred to as “TD-3”).
- R represents a hydroxyl group, and R represents a methoxy group.
- TD-6 (Hereinafter, referred to as “TD-6”).
- TD-5 (Hereinafter, referred to as “TD-5”).
- an anti-acute myeloid leukemia agent comprising one or more known compounds represented by the following general formula can be provided.
- R 1 represents a hydrogen atom and R represents a hydroxyl group (TD-9); R represents a hydrogen atom; R force
- R and R are methoxy
- An anti-ovarian cancer agent or an anti-prostate cancer agent containing a compound having 34 groups (TD-1) as an active ingredient can be provided. Further, the present invention provides an anti-ovarian cancer agent or an anti-prostate cancer agent used for treatment of ovarian cancer or prostate cancer.
- novel compound provided in the first aspect of the present invention is a compound of the above general formula (I), wherein R represents a hydroxyl group and R represents a hydroxyl group (TD-3); (II)
- R represents a hydroxyl group and R represents a methoxy group (TD-6);
- TD-5 is an isomer conjugate having a different conformation from the conjugate described in Technical Document 8, and specifically, the hydroxy group of the 3-hydroxy-1-butyl group has a 3S configuration. It is a new dangling product that has been considered a seat.
- the novel conjugates TD-3, TD-5 and TD-6 according to the present invention can improve immunity, activate metabolic function, reduce and kill germs, prevent excessive inflammation or allergy. It can be used as an active ingredient that has a suppressive effect, suppresses and cures lifestyle-related diseases (such as diabetes) and immune diseases.
- "TD-3” and “TD-6” have anticancer properties, preferably leukemia (more preferably acute myeloid leukemia). Therefore, the novel conjugates “TD-3” and “TD-6” are regarded as active ingredients of anticancer agents, and these anticancer agents can be used for cancer treatment.
- TD-3 and TD-6 are used as known pharmaceutical carriers in accordance with various administration forms. It can be formulated in combination with.
- parenteral administration by subcutaneous injection, intravenous injection, intramuscular injection, suppository, etc., or oral administration by tablet, capsule, powder, granule, etc., ointment, lotion, suppository, aerosol
- topical administration such as an agent can be exemplified.
- the dose can be appropriately determined according to the age, weight, and symptoms of animals and humans.
- an anti-acute myeloid leukemia agent comprising one or more known compounds.
- TD-1 "TD-2”, “TD-4”, “TD-7”, “TD-8”, “TD-9”, “TD-10” are known compounds It is.
- These experimental results have shown that these known compounds have excellent inhibitory and therapeutic effects on acute myeloid leukemia in animals or humans (preferably). Therefore, these TD compounds can be used as anti-acute myeloid leukemia agents containing them as active ingredients.
- the medicament and the dosage form are the same as those described in the first embodiment of the present invention.
- TD-1 an anti-ovarian cancer agent or an anti-prostate cancer agent comprising the known compound “TD-1” as an active ingredient. Additional studies have shown that TD-1 has excellent inhibitory and therapeutic effects on ovarian or prostate cancer in animals or humans (preferred). Therefore, TD-1 contains this as an active ingredient It can be used as an anti-ovarian cancer or anti-prostate cancer agent.
- the drug and the dosage form as a pharmaceutical may be the same as those described in the first embodiment of the present invention.
- the raw material is extracted with a solvent
- the extract is supplied to ion exchange chromatography, and a first lower alcohol, a second lower alcohol, and a lower ester, if necessary, are solvent-extracted in this order, and the second lower alcohol fraction is extracted. And obtaining a composition comprising TD-1-10.
- the raw material may be any as long as it contains a significant amount of TD-1-10 (and TD-11-114), and is preferably an Asteraceae plant or an Acabanaceae plant of the genus Ilex. .
- asteraceous plants include -tobegiku [(Tissoa diversifolia (Hemsl) A, Gray: “Tithonia diversifolia (Hemsl) A, Gray”, (as a family member, Teisoa.
- Fraticosa Canby & Rose "Tithonia fruticosaCanby & Rose", (Tissonia 's power verimaa' Bens: “Tithonia scaberrima Benth”), (Tissonia your longerradiata (bartle) break: “Tithonia longeradiata” (Bertol) Blake ”)] and about 10 kinds of Mexican sunflower [scientific name: Tissonia 'Mouth Tandifolia (Mill) Blake:” Tithonia rotundifolia (Mill) Blake] ".
- plants belonging to the genus Acacia genus include, but are not limited to, kidchikinbai ((Ludwigia octovalvis) Raven: “Ludwigia octovalvis Raven”) and caudatum (Rudwigia prostrataRoxbJ).
- a lower alcohol having 115 carbon atoms preferably ethanol
- the first lower alcohol and the second lower alcohol may be the same or different, but are preferably different.
- the first lower alcohol and the second lower alcohol include those having 116, preferably 113 carbon atoms.
- a combination in which the first lower alcohol is ethanol and the second lower alcohol is ethanol is preferably exemplified.
- the heating temperature at which heating may be performed is from 20 ° C to 100 ° C, preferably the upper limit is 80 ° C or lower, and the lower limit is 1 ° C or higher.
- the ion exchange chromatography to be used includes a column filled with an ion exchange substance (preferably a porous ion exchange resin: for example, "Diaion HP-20" manufactured by Mitsubishi Chemical Corporation).
- an ion exchange substance preferably a porous ion exchange resin: for example, "Diaion HP-20” manufactured by Mitsubishi Chemical Corporation.
- the solvent is preferably evaporated and concentrated to obtain a composition containing the TD-110 compound as an extract.
- a method for isolating a compound of TD-1-10 comprises preparing a composition comprising TD-1-10,
- a composition comprising TD-1-10 is obtained by the method for producing a composition comprising TD-1-10 described above.
- the separation solvent water, acetone, chloroform, lower alcohol having 5 or less carbon atoms, lower ester having 5 or less carbon atoms, and a mixed solvent thereof can be used.
- the mouth chromatography used is of normal phase or reversed phase, and a porous material (preferably silica gel) may be used as a filler.
- (high-speed) liquid chromatography can be used. In the present invention, it is preferable to isolate the TD compound by a combination of these chromatography.
- Specific examples of the method for isolating the TD-110 compound according to the present invention include the following methods. I can get lost. Therefore, the column packing material, chromatography, extraction solvent, etc. are the same as described in the method for isolating the TD compound above.
- a method for separating a composition containing TD-1-10 into a first composition containing TD-1-8 and a second composition containing TD-9 and 10, respectively comprises separating a composition comprising TD-111 by normal phase column chromatography followed by reverse phase column chromatography, wherein the first composition comprising TD-118 And a second composition comprising TD-9 and 10.
- TD-1-1 10 from a first composition containing TD-1-8 and a second composition containing TD-9 and 10, respectively. Is done. The details are as follows.
- the first composition containing TD-1-18 is subjected to repeated normal-phase or reversed-phase (silica gel) column chromatography, followed by (high-performance) liquid chromatography to obtain TD-1, TD2, TD — 4, TD-5 can be isolated.
- the first composition containing TD-118 is subjected to reverse phase silica gel column chromatography, reverse phase silica gel column chromatography, and high performance liquid chromatography equipped with a reverse phase silica gel column.
- reverse phase silica gel column chromatography reverse phase silica gel column chromatography
- high performance liquid chromatography equipped with a reverse phase silica gel column.
- the first composition containing TD-11 is repeatedly subjected to normal phase or reverse phase silica gel column chromatography to isolate TD-3 and TD-3, respectively.
- the first composition containing TD-118 is sequentially separated and purified by normal phase silica gel column chromatography, reverse phase silica gel column chromatography, and reverse phase silica gel column chromatography. By doing so, TD-3 and TD-7 can be isolated respectively.
- the first composition containing TD-118 is subjected to normal or reverse phase silica gel column chromatography.
- TD-6 and 8 can be isolated respectively.
- the first composition containing TD-118 is sequentially separated and purified by normal phase silica gel column chromatography, reverse phase silica gel column chromatography, and reverse phase silica gel column chromatography. By doing so, TD-6 and TD-8 can be isolated respectively.
- the second composition comprising TD-9 and 10 can be subjected to repeated normal or reverse phase silica gel column chromatography to isolate TD-9 and 10, respectively.
- the second composition comprising TD-9 and TD-9 is sequentially purified by normal-phase silica gel column chromatography, normal-phase silica gel column chromatography, and reverse-phase silica gel column chromatography. Can isolate TD-9 and TD-10, respectively.
- the method for producing the composition comprising TD-11-11 may be the same as that described in the section 1)
- Production method (extraction method) of the composition comprising TD-1-10 S and Mm ⁇ described in the section 1) may be the same in the method for producing a composition containing TD-11-114.
- TD-11-114 may be obtained as a composition mixed with TD-111 by this production method.
- a method for isolating the compound of TD-11-114 comprising the steps of: providing a composition comprising TD-11-114;
- the isolation of TD-11-114 may be the same as described for the isolation of TD-11-110.
- TD-11-14 may be obtained as a composition mixed with TD-11-10 by this isolation.
- a third composition containing TD-11 and TD-14 is obtained from a composition containing TD-11-11.
- a method can be provided for separating the composition and a fourth composition, each comprising TD-12 and TD-13. The method comprises separating a composition comprising TD-11-114 by normal phase column chromatography, followed by reverse phase column chromatography, and a third composition comprising TD-11 and 14; 13 into a fourth composition.
- a method for obtaining a first composition-a fourth composition using a composition containing TD-11-TD-14 can be carried out in the same manner as in 1-2) fractionation of a composition containing TD-1-10 and 2-2) fractionation of a composition containing TD-11-114.
- the first composition containing TD-11 is separated by separating the composition containing TD-11-TD-14 by normal phase column chromatography and then by reverse phase column chromatography.
- a second composition containing TD-9 and TD-10, a third composition containing TD-11 and TD-14, and a fourth composition containing TD-12 and TD-13, respectively. can do.
- TD-11 and TD-14 can be isolated using the first composition to the fourth composition by the method described above or below. .
- the third composition comprising TD-11 and 14 can be subjected to repeated normal or reverse phase silica gel column chromatography to isolate TD-11 and 14, respectively.
- the third composition comprising TD-11 and TD-11 is sequentially separated and purified by normal-phase silica gel column chromatography, reverse-phase silica gel column chromatography, and reverse-phase silica gel column chromatography. By doing so, TD-11 and TD-14 can be isolated, respectively.
- the fourth composition comprising TD-12 and 13 can be subjected to repeated normal or reverse phase silica gel column chromatography to isolate TD-12 and 13, respectively.
- the fourth composition comprising TD-12 and TD-12 is sequentially purified by normal-phase silica gel column chromatography, reverse-phase silica gel column chromatography, and reverse-phase silica gel column chromatography. Can isolate TD-12 and TD-13, respectively.
- This concentrated extract (320 g) was packed in an ion exchange column chromatography (ion exchange agent: Diaion HP-20). Next, a first alcohol solvent (methanol: water ratio of 50% or more) is flowed, then 45 liters of the second alcohol solvent (80% ethanol) is flowed, and finally, a lower ester, ethyl acetate, is flown. Then, the mixture was heated and extracted at 65 ° C for 2 hours to obtain a second alcohol fraction. After filtering the second alcohol fraction to remove impurities, the second alcohol solvent was evaporated to obtain a concentrated extract.
- ion exchange agent Diaion HP-20
- this extract (320 g) was subjected to normal-phase silica gel column chromatography (solvent with a ratio of black form to methanol of 9: 1), and then reversed-phase silica gel column chromatography (filler: ODS silica gel, methanol and water).
- TD fraction (containing TD-11), 2-2 fraction (containing TD-11 and 14), 2-3 fraction (TD solvent).
- TD solvent — Containing 9 and 10) and 2-4 fractions (containing TD-12 and 13), respectively.
- normal-phase silica gel column chromatography the difference in adsorption power between silica gel, the stationary phase,
- a portion of the 2-1 fraction was subjected to normal-phase silica gel column chromatography (solvent with a ratio of chromatoform and acetone of 49: 1 and 19: 1), and reversed-phase silica gel column chromatography (a ratio of methanol to water of 3: 1). : TD-6 (14. Omg) and TD-8 (8.7 mg) by successive purification by reversed-phase silica gel column chromatography (solvent with a ratio of acetonitrile to water of 1: 2). Isolated.
- Fractions 2-3 are subjected to normal-phase silica gel column chromatography (solvent with a ratio of chromatoform to acetone of 19: 1, 4: 1, and 2: 1), and normal-phase silica gel column chromatography (hexane and acetone). 9: 1, 7: 3 solvent), reverse phase silica gel column chromatography (9: 1, 4: 1, 3: 1, 2: 1, 1: 1 ratio of acetate nitrile to water) TD-9 (8.4 mg) and TD-10 (7.8 mg) were isolated.
- the 2-2 fraction was subjected to normal phase silica gel column chromatography (solvent with a ratio of chromatoform and acetone of 9: 1), reverse phase silica gel column chromatography (a solvent with a methanol to water ratio of 1: 1), TD-11 (67.9 mg) and TD-14 (8.7 mg) were purified by single-phase silica gel column chromatography (solvent with a ratio of acetonitrile to water of 3: 1, 5: 8, 1: 2). Released.
- Fractions 2-4 were subjected to normal-phase silica gel column chromatography (the ratio of Is a 1: 1, 3: 2 solvent), reversed-phase silica gel column chromatography (solvent with a methanol to water ratio of 1: 1), and reversed-phase silica gel column chromatography (acetonitrile to water ratio of 1: 2, 1) TD-12 (18.8 mg) and TD-13 (60.8 mg).
- TD-3, TD-5, and TD-6 which are novel conjugated substances, were determined based on the following spectral data and the like.
- TD-1, TD-2, TD-4, TD-7, TD-8, TD-9, and TD-10 are known compounds, and various spectral data are described in the contents of the above-mentioned technical literature 113. These structures were determined based on this. Specifically, it was as follows.
- TD-11-114 are known compounds, and their structures were determined based on the contents of various spectral data described in the above-mentioned Technical Documents 10-13. Specifically, it was as follows o
- TD-1 1 (generic name: tagitinin F)
- TD-1 2 (generic name: Luteolin)
- TD-13 (generic name: Netin)
- the anticancer activity of TD-11 was examined by the numerical value of cytotoxic activity using human acute myeloid leukemia cell line HL-60. Specifically, the test was performed as follows.
- the number of HL-60 cells pre-cultured in RPMI1640 medium containing FBS was suspended in RPMI1640 medium containing FBS so that the number of HL-60 cells became 4 ⁇ 10 4 cells in ImL, and 196 mL of the suspension was added to each well of a 96-well microplate.
- Each of the solutions was pre-incubated at 37 ° C in 5% carbon dioxide for 24 hours. Then, EtOH-H0 (1: 1) as a control and each TD compound as a sample
- the IC value (g / mL) of TD-10 was as shown in Table 1 below.
- TD-1 human cultured cancer cell panel screening test was performed. Specifically, the human cultured cancer cell panel screening test was performed on all TD-1s in accordance with the method described in “Cancer and Danikyo Therapy (Takao Yamori), 24, 129-135, 1997”. It is performed by measuring the 50% cytostatic concentration (GI) for 39 human tumor cells.
- GI cytostatic concentration
- OVCAR-5 2. 9 OVCAR-8 3.6
- TD-1 has a total of 39 GI values for ovarian and prostate cancer cell lines.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Plant Substances (AREA)
- Furan Compounds (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/580,588 US7563913B2 (en) | 2003-11-27 | 2003-11-25 | Compound and pharmaceutical composition |
EP04819399A EP1688419A4 (en) | 2003-11-27 | 2004-11-25 | NEW CONNECTION AND MEDICAL COMPOSITION |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-397647 | 2003-11-27 | ||
JP2003397647 | 2003-11-27 | ||
JP2004265620A JP3816504B2 (ja) | 2003-11-27 | 2004-09-13 | 新規化合物および医薬組成物 |
JP2004-265620 | 2004-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005051955A1 true WO2005051955A1 (ja) | 2005-06-09 |
Family
ID=34635618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/017480 WO2005051955A1 (ja) | 2003-11-27 | 2004-11-25 | 新規化合物および医薬組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7563913B2 (ja) |
EP (1) | EP1688419A4 (ja) |
JP (1) | JP3816504B2 (ja) |
WO (1) | WO2005051955A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102764284A (zh) * | 2012-07-11 | 2012-11-07 | 中国人民解放军第二军医大学 | 肿柄菊倍半萜提取物及其制备方法和用途 |
CN114315850A (zh) * | 2021-12-06 | 2022-04-12 | 南京中医药大学 | 菊芋倍半萜内酯及其药用衍生物与在抗急性髓性白血病中的应用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4541728B2 (ja) * | 2004-03-09 | 2010-09-08 | 株式会社コーセー | 皮膚外用剤 |
FR2941697A1 (fr) * | 2009-02-02 | 2010-08-06 | Pf Medicament | Derives de tagitinine c et f comme agents anticancereux. |
TWI428137B (zh) * | 2011-07-14 | 2014-03-01 | Hsiang Ru Lin | Treatment of Metabolic Diseases by Lactarius and Its Derivatives |
KR101378433B1 (ko) * | 2012-11-05 | 2014-03-27 | 초당약품공업 주식회사 | 세스퀴터핀 락톤계 위장 질환 치료용 의약 조성물 |
CN105153086A (zh) * | 2015-10-26 | 2015-12-16 | 沈健龙 | 一种新的倍半萜类化合物及其制备方法和医药用途 |
CN105669605A (zh) * | 2016-01-14 | 2016-06-15 | 郑平珍 | 一种新的二萜类化合物及其制备方法和医药用途 |
DOP2018000291A (es) * | 2018-12-20 | 2019-08-15 | Univ Autonoma De Santo Domingo Uasd | LACTONAS SESQUITERPÉNICAS DE Koanophyllon gibbossum, Y SU USO PARA EL TRATAMIENTO DE DISTINTOS TIPOS DE CÁNCER. |
CN116554136A (zh) * | 2023-04-23 | 2023-08-08 | 五邑大学 | 一种具有抗前列腺癌活性的倍半萜内酯及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02264722A (ja) * | 1989-04-04 | 1990-10-29 | Tsumura & Co | 抗癌剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2609780B2 (ja) | 1990-08-30 | 1997-05-14 | 正清 高橋 | 糖尿病治療薬 |
JPH08127538A (ja) | 1994-10-31 | 1996-05-21 | Masakiyo Takahashi | 糖尿病治療薬 |
-
2003
- 2003-11-25 US US10/580,588 patent/US7563913B2/en not_active Expired - Fee Related
-
2004
- 2004-09-13 JP JP2004265620A patent/JP3816504B2/ja not_active Expired - Fee Related
- 2004-11-25 WO PCT/JP2004/017480 patent/WO2005051955A1/ja active Application Filing
- 2004-11-25 EP EP04819399A patent/EP1688419A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02264722A (ja) * | 1989-04-04 | 1990-10-29 | Tsumura & Co | 抗癌剤 |
Non-Patent Citations (7)
Title |
---|
BARUAH NABIN C. ET AL: "Sesquiterpene Lactones of Tithonia diversifolia. Stereochemistry of the Tagitinins and Related Compounds", JOURNAL OF ORGANIC CHEMISTRY, vol. 44, 1979, pages 1831 - 1835, XP008095310 * |
KOBAYASHI R. ET AL: "Kikuka Shokubutsu Tithonia diversifolia (Nitobegiku) no Sesquiterpenoid Seibun ni Tsuite", NIPPON YAKUGAKUKAI NENKAI KOEN YOSHISHU, vol. 124, no. 2, 5 March 2004 (2004-03-05), pages 139, XP001537862 * |
PAL R. ET AL: "Antileukemic and Other Constituents of Tithonia Tagitiflora Desf.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 65, no. 6, 1976, pages 918 - 920, XP008095317 * |
PAL R. ET AL: "Chemical Constituents of Tithonia tagitiflora Desf.: Part III-Constitution of Tagitinin-A", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMICAL INCLUDING MEDICINAL CHEMISTRY, vol. 14B, 1976, pages 259 - 262, XP009096591 * |
PAL R. ET AL: "Chemical Constituents of Tithonia tagitiflora Desf.: Part IV-Tagitinin-C, D & F", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMICAL INCLUDING MEDICINAL CHEMISTRY, vol. 15B, 1977, pages 208 - 211, XP009096590 * |
PEREIRA P.S. ET AL: "Sesquiterpene Lactones from Brazilian Tithonia Diversifolia", PHYTOCHEMISTRY, vol. 45, 1997, pages 1445 - 1448, XP004293284 * |
See also references of EP1688419A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102764284A (zh) * | 2012-07-11 | 2012-11-07 | 中国人民解放军第二军医大学 | 肿柄菊倍半萜提取物及其制备方法和用途 |
CN114315850A (zh) * | 2021-12-06 | 2022-04-12 | 南京中医药大学 | 菊芋倍半萜内酯及其药用衍生物与在抗急性髓性白血病中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP3816504B2 (ja) | 2006-08-30 |
EP1688419A4 (en) | 2008-04-30 |
JP2005179339A (ja) | 2005-07-07 |
US7563913B2 (en) | 2009-07-21 |
US20070129427A1 (en) | 2007-06-07 |
EP1688419A1 (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
An et al. | Diarylheptanoids from the rhizomes of Alpinia officinarum and their anticancer activity | |
Long et al. | Indole alkaloids from the aerial parts of Kopsia fruticosa and their cytotoxic, antimicrobial and antifungal activities | |
Kadota et al. | Novel diarylheptanoids of Alpinia blepharocalyx | |
Yadav et al. | Antioxidant furofuran lignans from Premna integrifolia | |
CN110305092B (zh) | 愈创木烷倍半萜及其制备和应用 | |
Sichaem et al. | Tabebuialdehydes A–C, cyclopentene dialdehyde derivatives from the roots of Tabebuia rosea | |
WO2005051955A1 (ja) | 新規化合物および医薬組成物 | |
TWI282280B (en) | Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same | |
CN110305014B (zh) | 环新木脂烷型木脂素对映异构体及其制备和应用 | |
Wu et al. | Clerodane diterpenes from Polyalthia longifolia var. pendula protect SK-N-MC human neuroblastoma cells from β-amyloid insult | |
KR100750500B1 (ko) | 항산화 활성을 갖는 신규 사가 크로마놀 유도체 화합물, 이의 분리방법 및 이를 포함하는 항산화제 | |
Fukuyama et al. | Cytotoxic iridoid aldehydes from Taiwanese Viburnum luzonicum | |
KR101737556B1 (ko) | 법제 하수오 추출물을 유효성분으로 포함하는 산화적 스트레스 개선용 조성물 | |
CN100413868C (zh) | 分离自藤黄树脂并具有抑制肿瘤/癌细胞生长活性的化合物以及包含其的药物组合物 | |
CN105884588B (zh) | 一种降倍半萜类化合物及其制备方法与应用 | |
Thi Dung et al. | Elsholblanosides A− D, Four New Oleuropeic Acid Derivatives Isolated from Elsholtzia blanda and Their Inhibition of NO Production in LPS‐activated RAW264. 7 Cells | |
WO2022254867A1 (ja) | 新規フェニルプロパノイド化合物 | |
Alishir et al. | Ulmusakidian, a new coumarin glycoside and antifungal phenolic compounds from the root bark of Ulmus davidiana var. japonica | |
CN115991692A (zh) | 菘蓝中螺二烯酮木脂素化合物的制备方法及其应用 | |
KR100833121B1 (ko) | 활성산소 소거활성이 있는 신규 화합물, 이의 제조방법 및이를 포함하는 조성물 | |
JP4511413B2 (ja) | 医薬組成物 | |
KR100809731B1 (ko) | (-)-세코이소라리시레시놀을 포함하는 약학 조성물 | |
Tang et al. | Cytotoxic melodinus-type alkaloids from the ethanol extract of Melodinus fusiformis | |
Issa et al. | New sesquiterpene lactones from the aerial parts of Pseudoelephantopus spicatus | |
JP2005298516A (ja) | 新規化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007129427 Country of ref document: US Ref document number: 10580588 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004819399 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004819399 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10580588 Country of ref document: US |